Prezista New Zealand - English - Medsafe (Medicines Safety Authority)

prezista

janssen-cilag (new zealand) ltd - darunavir ethanolate 650.46mg equivalent to darunavir 600 mg - film coated tablet - 600 mg - active: darunavir ethanolate 650.46mg equivalent to darunavir 600 mg excipient: crospovidone magnesium stearate opadry orange 85f13962 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

PREZISTA™ TABLET 600MG Singapore - English - HSA (Health Sciences Authority)

prezista™ tablet 600mg

johnson & johnson international (singapore) pte ltd - darunavir ethanolate 650.46 mg eqv darunavir; darunavir ethanolate eqv darunavir - tablet, film coated - 600mg - darunavir ethanolate 650.46 mg eqv darunavir 600mg; darunavir ethanolate eqv darunavir 600mg

PAT-DARUNAVIR TABLET Canada - English - Health Canada

pat-darunavir tablet

patriot a division of janssen inc - darunavir (darunavir ethanolate) - tablet - 600mg - darunavir (darunavir ethanolate) 600mg - hiv protease inhibitors

PREZISTA- darunavir ethanolate tablet, film coated United States - English - NLM (National Library of Medicine)

prezista- darunavir ethanolate tablet, film coated

state of florida doh central pharmacy - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir ethanolate 400 mg - prezista® , co-administered with ritonavir (prezista/ritonavir), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment-naïve and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients. prezista, co-administered with ritonavir (prezista/ritonavir), and with other antiretroviral agents, is indicated for the treatment of hiv infection in pediatric patients 6 years of age and older [see use in specific populations (8.4) ]. this indication is based on 24-week analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric patients, the following poi

AURO-DARUNAVIR TABLET Canada - English - Health Canada

auro-darunavir tablet

auro pharma inc - darunavir (darunavir propylene glycolate) - tablet - 400mg - darunavir (darunavir propylene glycolate) 400mg - hiv protease inhibitors

AURO-DARUNAVIR TABLET Canada - English - Health Canada

auro-darunavir tablet

auro pharma inc - darunavir (darunavir propylene glycolate) - tablet - 600mg - darunavir (darunavir propylene glycolate) 600mg - hiv protease inhibitors

AURO-DARUNAVIR TABLET Canada - English - Health Canada

auro-darunavir tablet

auro pharma inc - darunavir (darunavir propylene glycolate) - tablet - 800mg - darunavir (darunavir propylene glycolate) 800mg - hiv protease inhibitors

PREZISTA- darunavir tablet, film coated United States - English - NLM (National Library of Medicine)

prezista- darunavir tablet, film coated

remedyrepack inc. - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir 600 mg - prezista ® , co-administered with ritonavir (prezista/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection in adult and pediatric patients 3 years of age and older [see use in specific populations (8.4) and clinical studies (14)] . co-administration of prezista/ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). these drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed in table 6 . due to the need for co-administration of prezista with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications. co-administration of prezista/ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are

PREZCOBIX- darunavir ethanolate and cobicistat tablet, film coated United States - English - NLM (National Library of Medicine)

prezcobix- darunavir ethanolate and cobicistat tablet, film coated

remedyrepack inc. - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg) - darunavir 800 mg - prezcobix ® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions (v11i, v32i, l33f, i47v, i50v, i54l, i54m, t74p, l76v, i84v, l89v). prezcobix is contraindicated in patients receiving the following co-administered drugs prezcobix is contraindicated in patients receiving the following co-administered drugs [see drug interactions (7.3) and clinical pharmacology (12.3)]. - alpha 1-adrenoreceptor antagonist: alfuzosin - anticonvulsants: carbamazepine, phenobarbital, phenytoin - anti-gout: colchicine, in patients with renal and/or hepatic impairment - antimycobacterial: rifampin - antipsychotics: lurasidone, pimozide - cardiac disorders: dronedarone, ivabradine, ranolazinecardiac disorders: dronedarone, ivabradine, ranolazine - ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine - gi motility agent: cisapride - he

PREZISTA- darunavir tablet, film coated
PREZISTA- darunavir suspension United States - English - NLM (National Library of Medicine)

prezista- darunavir tablet, film coated prezista- darunavir suspension

janssen products lp - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir 75 mg - prezista, co-administered with ritonavir (prezista/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection in adult and pediatric patients 3 years of age and older [see use in specific populations (8.4)and clinical studies (14)] . co-administration of prezista/ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). examples of these drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below [see drug interactions (7.3)] . due to the need for co-administration of prezista with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications. - alpha 1-adrenoreceptor antagonist: alfuzosin - anti-gout: colchicine, in patients with renal a